IBRX
ImmunityBio, Inc.
There isn't enough reported data to score IBRX yet.
IBRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
IBRX's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
IBRX PE Valuation
IBRX has no meaningful PE right now: it lost money over the past year.
IBRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IBRX's losses to grow, with revenue growing. However, they disagree widely on these estimates.
IBRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.08 | -$0.68 |
| Q2 2026 | -$0.97 | -$0.50 |
| Q1 2026 | -$0.85 | -$0.28 |
| Q4 2025 | -$0.38 | +$0.24 |
| Q3 2025 | -$0.40 | +$0.51 |
| Q2 2025 | -$0.47 | +$0.49 |
| Q1 2025 | -$0.57 | +$0.51 |
| Q4 2024 | -$0.62 | +$0.53 |
IBRX lost $1.08 per share over the past year, and its loss has widened in each of the last three quarters.
IBRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $48.8M | +52% |
| Q2 2026 | $51.2M | +94% |
| Q1 2026 | $44.2M | +168% |
| Q4 2025 | $38.3M | +407% |
| Q3 2025 | $32.1M | +425% |
| Q2 2025 | $26.4M | +2424% |
| Q1 2025 | $16.5M | +41193% |
| Q4 2024 | $7.6M | +5333% |
IBRX's revenue has grown year over year for 10 quarters in a row: $49M last quarter, up 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -160% | +14 points |
| Q2 2026 | -120% | +149 points |
| Q1 2026 | -158% | +232 points |
| Q4 2025 | -169% | +750 points |
| Q3 2025 | -174% | +1141 points |
| Q2 2025 | -270% | +9218 points |
| Q1 2025 | -390% | +237600 points |
| Q4 2024 | -919% | +60512 points |
IBRX's operating margin was −160% last quarter, up 14 points from the same quarter a year ago.
IBRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$78.3M | -$8.6M |
| Q2 2026 | -$70M | +$10.8M |
| Q1 2026 | -$77.1M | +$9.9M |
| Q4 2025 | -$71.3M | +$16M |
| Q3 2025 | -$69.6M | +$31.9M |
| Q2 2025 | -$80.8M | +$20.2M |
| Q1 2025 | -$87M | +$21.2M |
| Q4 2024 | -$87.3M | +$36M |
IBRX has burned cash in almost every quarter: −$297M over the past year, against −$325M the year before.
IBRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +10.9M shares |
| 1 year | +12% | +114M shares |
| 3 years | +143% | +623M shares |
| 5 years | +176% | +676M shares |
| Available history | +978% | +963M shares |
IBRX has 1.1B diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q4 2019 | — |
IBRX Net Leverage
IBRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IBRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 29.3 | Neutral |
IBRX's weekly RSI is 39 (neutral) and its Stochastic is 29 (neutral).
IBRX PE vs Healthcare Sector
IBRX has no meaningful PE right now: it lost money over the past year.
IBRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.70 | 30% below |
| 20 week MA | $8.24 | 26% below |
| 50 week MA | $7.15 | 15% below |
| 100 week MA | $4.93 | 23% above |
| 200 week MA | $4.42 | 37% above |
IBRX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
IBRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.74 | $16.0 | +328% |
| 2021 | $16.0 | $7.15 | -55% |
| 2022 | $7.15 | $5.46 | -24% |
| 2023 | $5.46 | $5.02 | -8.1% |
| 2024 | $5.02 | $2.78 | -45% |
| 2025 | $2.78 | $2.14 | -23% |
| 2026 YTD | $2.14 | $6.07 | +184% |
IBRX has finished five years in a row lower, and it's up 184% so far in 2026.